KirshRGoldsteinRTarloffJParrisDHookJHannaN. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis1988; 158: 1065–70.
2.
MoreauPMilpiedNFayetteNRaméeJ-FHarousseauJL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutrogenic patients. J Antimicrob Chemother1992; 30: 535–41.
3.
ChavanetPYGarryICharlierNCaillotDKistermanJPD'AthisM. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected parients with candidiasis. BMJ1992; 305: 921–5.
4.
VitaESchroederDJ. Intralipid in prophylaxis of amphotericin B nephrotoxicity. Ann Pharmacother1994; 28: 1182–3.
5.
SmithTMStrozykWR. Lack of nephrotoxocity with the administration of amphotericin B in a lipid emulsion. Ann Pharmacother1994; 28: 1307–8.
6.
JurgensRWDeLucaPPPapadimitriouD. Compatibility of amphotericin B with certain large-volume parenterals. Am J Hosp Pharm1981; 38: 377–8.
7.
MargosisMAszalosA. Quantitation of amphotericin by reversephase high-performance liquid chromatography. J Pharm Sci1984; 73: 835–8.
